section name header

Pronunciation ⬇

ne-BI-vi-lol

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers (selective)

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Blocks stimulation of beta adrenergic receptor sites; selective for beta1 (myocardial) receptors in most patients. In some patients (poor metabolizers), higher blood levels may result in some beta2 (pulmonary, vascular, uterine) adrenergic blockade.
Therapeutic effects:
  • Lowering of BP.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 98%.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP2D6 isoenzyme; the CYP2D6 enzyme system exhibits genetic polymorphism; ∼7% of population may be poor metabolizers and may have significantly ↑ nebivolol concentrations and an ↑ risk of adverse effects.; minimal excretion of unchanged drug.

Half-Life: Extensive metabolizers: 12 hr; Poor metabolizers: 19 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1.5–4 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Endo: hypoglycemia

Neuro: dizziness, fatigue, headache

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Hepatic/Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Bystolic

Code ⬆

NDC Code